| FTNT |
Report |
Total Revenue (Q2'26) |
BEAT |
pred ~$1.92B vs. cons $1.88B |
MEDIUM |
| FTNT |
Report |
Billings (Q2'26) |
BEAT |
pred ~$2.20B vs. cons $2.13B |
MEDIUM |
| FTNT |
Report |
Non-GAAP EPS (Q2'26) |
BEAT |
pred ~$0.80 vs. cons $0.75 |
MEDIUM |
| FTNT |
Guide |
FY2026 Revenue Guidance |
BETTER |
guide ~$7.85-7.95B vs. cons $7.80B (FY2026) |
MEDIUM |
| FTNT |
Guide |
FY2026 Billings Guidance |
BETTER |
guide ~$8.95-9.20B vs. cons $8.95B (FY2026) |
LOW |
| FTNT |
Guide |
FY2026 Non-GAAP EPS Guidance |
UNCHANGED |
guide ~$3.10-3.20 vs. cons $3.15 (FY2026) |
MEDIUM |
| FTNT |
Guide |
Q3'26 Non-GAAP Operating Margin Guidance |
UNCHANGED |
guide ~33-35% vs. cons ~34% (Q3 2026) |
LOW |
| FTNT |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
MEDIUM |
| FTNT |
Return |
5-day cumulative residual |
-5.0% (FADE) |
Stock is priced for perfection after >100% run and 52x forward P/E vs 42x 5-yr avg, with analyst price targets ~20% below spot; a beat-and-raise that is only incremental relative to already-elevated buy-side whisper numbers (vs Q1's 20%+ growth blowout) is likely to trigger profit-taking. Second-half guidance is expected to remain 'prudent' (per Barclays channel checks) rather than aggressively raised, limiting forward EPS/revenue revision momentum; implicit deceleration from Q1's ~31% billings growth pace toward the ~20% guided range means out-quarter estimates get trimmed even after a headline beat, causing initial reaction to fade over the week as investors digest normalizing growth against a still-rich multiple and mixed AI-capex sentiment backdrop. |
LOW |